Cancer%20pain Signs and Symptoms

Signs and Symptoms

Introduction

Effective pain management in cancer patients with pain is an essential part of oncologic management due to increasing evidence of survival

Chronic pain syndrome also often occurs following cancer treatments

Pancreatic, head and neck cancer has a high prevalence of cancer pain
During initial evaluation, follow-ups and new therapy initiation of patients with cancer, it is essential that they be screened and evaluated for pain

Definition

An unpleasant sensory and emotional experience due to actual or potential tissue damage in patients with cancer

Neoadjuvant Treatment of Early Breast Cancer

14 Mar 2017

Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.

Child-Pugh score a prognostic factor for sorafenib response in HCC patients?

Jairia Dela Cruz, 06 Dec 2016

Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.

Comprehensive molecular profiling: Expanding therapeutic options in advanced cancers

Dr. Alexander Drilon, 19 Jul 2017

With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).